EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 我们继续与拜耳先灵制药在血栓形成和止血领域进行合作研究。我们正在进行一项研究项目，以确定拜耳提供的PAR1拮抗剂是否具有治疗血栓栓塞性疾病的潜力。首先，5个化合物将在体外进行评估，1个化合物将在体内进行测试。随后，三种化合物将进行体外评价，两种化合物将进行体内评价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. We continue our collaborative research with Bayer Schering Pharma in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, five compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, three compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.